The opportunity exists for accredited investors as defined in Rule 501(a) of Regulation D of the US Securities Act of 1933, to express interest to invest in Aquyre Biosciences. 

Aquyre Biosciences provides tissue adequacy assessment thru tissue micro-architecture delineation and intracellular data acquisition. The company's system provides a rapid on-site microscopic optical image of unstained surgical specimens immediately after resection, proprietary data used to create automated diagnosis algorithms, helping physicians to assist in forming a clinical judgment and rapidly and accurately identify cancer, immune and other cells. Its Full-Field Optical Coherence Tomography (FFOCT) offers en face (transverse), high resolution, 3D imaging of the tissue micro-architecture, at a resolution of 1μm. FFOCT also allows for depth exploration at different focal planes, without compromising 1μm resolution and is designed to capture data and present results in a few minutes from fresh live biopsies in the operating theatre. While the company's Dynamic Cell Imaging (DCI) enhances the cellular contrast by capturing the residual microscopic intracellular activity and behaviours in freshly excised tissue, without staining or partially destroying the tissue.

If you would like more information, click Register Interest below.